Coronavirus (COVID-19)
Learn more
April 27, 2017
Sponsor: Pfizer
Number: B3281006
This study will compare the safety and effectiveness of PF-05280586 versus Rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of Rituximab-EU.
Who’s eligible:
Available at: The Hospital of Central Connecticut- The Cancer Center of Central Connecticut.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.